ࡱ> ;=89: bjbj]W]W =f?=?=YB.p$8 ,w! $""$"$"$V%H*l+5w7w7w7w7w7w7w$zr}:[w5V%V%55[w"$"$4pw;;;5"$"$5w;55w;;2kvp"$@s̻6$%n.!ww<wSn}7V}\pp}r|l,12>l,l,l,[w[w":l,l,l,w5555}l,l,l,l,l,l,l,l,l, : 3.8 IMMUNIZATIONS   PURPOSE To ensure that every child and adult refugee is appropriately immunized against vaccine-preventable diseases. BACKGROUND Outbreaks of vaccine-preventable diseases occur overseas as well as in the United States. Highlighting this risk, the CDC has documented outbreaks of vaccine-preventable diseases. An estimated 20 million cases of measles occur each year worldwide, and cases continue to be imported into the United States. Imported measles cases can result in large outbreaks, particularly if introduced into areas with pockets of unvaccinated persons.,, In 2005 mumps cases in Indiana as well as widespread mumps outbreak in the Midwest. Globally, high infant and child mortality from vaccine preventable diseases has led to major childhood immunization efforts. While vaccination programs are incorporated into refugee health services, most refugee children and adults come to the United States with high risk of under-immunization. United States-bound refugees may receive additional vaccinations pre-departure; the schedules as of September 2012 are available  HYPERLINK "http://www.cdc.gov/immigrantrefugeehealth/guidelines/domestic/immunizations-guidelines.html" on-line. Recommendations for child and adult immunizations change. Integration of newer vaccines combined with changes in guidelines for older vaccines may present challenges for clinical logistics. The extra burden of these vaccination changes for both patient and clinic staff are notable; however, clinics must overcome such challenges to ensure that refugee patients are on the path to being fully immunized according to the vaccine schedules of the CDCs Advisory Committee on Immunization Practices (ACIP) and the MDPH Immunization Program. RIHP always requires clinicians to follow the latest ACIP routine and catch-up scheudules for both children and adults which can be found on the  HYPERLINK "http://www.cdc.gov/vaccines/schedules/index.html" CDC website.In addition,  HYPERLINK "http://www.cdc.gov/vaccines/hcp/acip-recs/index.html" detailed guidance from the ACIP about each vaccine can be found on their website. Massachusetts school entry vaccine requirements are on the  HYPERLINK "http://www.mass.gov/eohhs/gov/departments/dph/programs/id/immunization/guidelines-and-schedules.html" MDPH Immunization Program website. All individuals applying to adjust their immigration status to Permanent Resident Alien are required to document vaccination in accordance with ACIP recommendations; vaccinations are recorded on the  HYPERLINK "http://www.uscis.gov/portal/site/uscis/menuitem.5af9bb95919f35e66f614176543f6d1a/?vgnextoid=eb1f3591ec04d010VgnVCM10000048f3d6a1RCRD&vgnextchannel=db029c7755cb9010VgnVCM10000045f3d6a1RCRD" USCIS Form I-693 by a Civil Surgeon. The RHAP provider plays an essential role in assuring that refugees meet the vaccine requirements. The recommendations in this manual are current as of October 2013. For updates, please see the  HYPERLINK "http://www.mass.gov/eohhs/gov/departments/dph/programs/id/immunization/guidelines-and-schedules.html" MDPH Immunization Program or  HYPERLINK "http://www.cdc.gov/vaccines/" CDC websites. Note: All Refugee Health Assessment Program sites must be enrolled and participate in the Vaccines for Children Program/MDPH Immunization Program. PROGRAM In brief, the RHAP requires the following of providers: REQUIREMENTS Evaluate immunization history, review overseas documentation including pre-departure documents and record valid doses on the RHAP form and/or the electronic health record. Initiate all necessary age-appropriate vaccines per ACIP adult and childhood vaccine schedules. Provide each refugee with a childhood or adult vaccination booklet, or equivalent document, with completed documentation of past and RHAP vaccination; update at the second visit. Order serum IgG levels against Varicella (chicken pox) for all refugees aged > 5 years of age. Vaccinate susceptible individuals. Clinicians may consider administering a single dose of vaccine pending the serology results to facilitate school entry. Blood should be drawn prior to immunization whenever possible (for Varicella and Hepatitis B serologies). Document immunity to varicella, based on exam, history or serologic testing. Educate refugees of the need to bring the immunization documentation to all medical visits including the Civil Surgeon evaluation required for change of status applications. All RHAP clinicians must follow all adult and childhood vaccine schedules and guidelines from the MDPH Immunization Program and ACIP. Because the basic RHAP process is two visits separated by approximately one month, it is not expected that RHAP providers will be able to administer complete vaccine series for refugees who need them. At a minimum, RHAP providers should initiate/continue appropriate vaccination at each RHAP visit, refer to primary care, and educate the refugee about school and USCIS requirements and follow-up timing to complete vaccine series. RHAP providers also have the option of scheduling pre-RHAP (for children) and post-RHAP (for adults) vaccine-only nursing visits to facilitate school entry for children or complete a primary vaccine series for adult refugees. RHAP reimburses these visits and the cost of vaccines procured by the site for immunizing adult refugees. Evaluation of immunization history through record review should determine any need for vaccination to achieve age-appropriate vaccination levels. The ACIP has clear guidelines on evaluation of immunization status for individuals vaccinated outside the United States. These are summarized below. Evaluating Findings The role of a provider during the health assessment is, first, to assess the immunization status of the patient (including serologic testing as described above); second, to proceed to vaccinate according to age in order to initiate or complete the required primary vaccine series; and third, to make recommendations to primary care for necessary follow-up in order to complete recommended vaccination. All refugees, especially parents of school-age children, should be educated about the importance of completing primary vaccine series and immunization requirements for school entry, daycare attendance, and future immigration status changes. With the exception of chicken pox, verbal or written report of a history of a disease is not considered adequate proof of immunity. Similarly, incomplete documentation of overseas vaccines may not be considered adequate for withholding vaccination. For example, a document with only a year for the vaccination date is not acceptable. Clinicians should not write phrases such as received in home country, up to date, or in time on the RHAP form or a personal vaccine document. These assertions will not be useful for school nurses or Civil Surgeon personnel guided by strict regulations. Instead, clinicians must inform refugees of the need for vaccines to assure immunity to vaccine-preventable disease and proceed with necessary immunizations per ACIP guidelines. Acceptability of The acceptability of vaccines received in other countries to meet Vaccinations Received vaccination requirements in the United States depends on three Outside the US factors: Vaccine potency, adequate documentation, and vaccination in accordance with the US immunization schedule. For complete guidance, see pages 27-29 and 49 in  HYPERLINK "http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf" ACIPs section on Persons Vaccinated Outside the United States in their General Recommendations on Immunization. 1. Vaccine Potency The majority of vaccines used worldwide are from reliable local or international manufacturers, and no potency problems have been detected, with the occasional exception of tetanus toxoid and OPV vaccines. 2. Adequate Documentation of Receipt of Vaccine Doses of vaccine with written documentation of the date of receipt should be accepted as valid. At a minimum, month and year must be a part of the date. Camp vaccination cards or Department of State forms are acceptable records. Self-reported doses of vaccine without written documentation should not be accepted, and patients should be considered susceptible. CDC notes that under mass vaccination campaigns conducted overseas for outbreak control, documentation may not be provided and therefore may not be recorded on the Department of State forms. Language translations for vaccine names are available at  HYPERLINK "http://www.immunize.org/catg.d/p5122.pdf" Immunization Action Coalition and  HYPERLINK "http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/foreign-products-tables.pdf" CDC. All adults and children should be started on the age-appropriate catch-up immunization schedule used in the United States. 3. Immunization Schedule Age at vaccination and spacing of vaccine doses must be assessed for acceptability. To be considered valid, the doses must meet the minimum age and intervals in the  HYPERLINK "http://www.cdc.gov/vaccines/schedules/index.html" U.S. immunization schedules posted on the CDC website. The minimum intervals of different vaccine antigens can be found in  HYPERLINK "http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/a/age-interval-table.pdf" Table 1 of the ACIPs General Recommendations on Immunization. DTP/DTaP: Age: Any dose of DTP/DTaP vaccine administered at > 6 weeks of age can be considered valid. Spacing: The first 3 doses of DTP/DTaP vaccine should have been separated by a minimum of 4 weeks. The 4th dose should have been administered no less than 6 months after the third dose. The 5th dose should have been adminstered no less than 6 months after the 4th dose and at 4 years of age or older. A 5th dose is not needed if the 4th dose was administered after 4 years of age or older. HIB: Age: Any dose of Hib vaccine administered at > 6 weeks of age can be considered valid. Spacing: Doses of Hib vaccine in the primary series should have been administered no less than 1 month apart. The booster dose of Hib vaccine should be administered at least 2 months after the previous dose, and should not be administered before age 15 months. POLIO: Age: Doses of OPV and IPV administered at > 6 weeks of age of age can be considered valid. This section refers to evaluation of overseas vaccination only. Current ACIP guidelines stipulate that in most circumstances, only IPV should be used in the United States. See below for further information. Spacing: The timing of vaccine doses varies depending on the schedule used: When interpreting records from oversees, please note bivalent OPV does not count as a valid dose towards meeting the recommendations/requirements for the U.S. schedule. Only trivalent doses of OPV or IPV should be counted. Sequential IPV/OPV: At least 4 weeks are needed between doses 1, 2, and 3, although an interval of 6-8 weeks is preferred. At least 4 weeks are needed between doses 3 and 4, although an interval of 6 months is preferred. When IPV and OPV are used in combination, 4 doses are always needed to complete the primary series. All OPV: At least 4 weeks are needed between doses 1, 2, 3, and 4; however, >6 months is preferred between the final doses in the series. For children who received all OPV, the third dose of OPV could be administered as early as 6 months of age. A minimum of 3 doses is needed to complete the primary series, if the final dose was administered at age > 4 years. All IPV: At least 4 weeks are needed between doses 1 and 2, and > 6 months between doses 3 and 4. The final dose in the IPV series should be administered at age >4 years regardless of the number of previous doses. A 4th dose IPV is not necessary if the 3rd dose was administered at 4 years of age or older and >6 months after the previous dose Any dose of polio vaccine administered at the above- recommended minimum intervals can be considered valid. Persons vaccinated outside the United States may need one or more additional doses of IPV to meet current immunization guidelines in the United States. NOTE: Current ACIP guidelines call for the use of all-IPV vaccine schedule in the United States. While most refugees will have received OPV overseas, RHAP clinicians should only use IPV except in specific circumstances described in the ACIP guidelines. See  HYPERLINK "http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/polio.html" ACIP recommendations for polio vaccine. MEASLES: Age: Any dose of measles vaccine administered at > 12 months of age can be interpreted as valid. Children vaccinated against measles before their first birthday should be revaccinated if they are now >12 months of age. The 2nd dose may be given at age 4-6 years, prior to school entry, provided > 4 weeks have elapsed since the prior dose. Spacing: Persons born in or after 1957 should have documentation of having received two doses of live measles vaccine and live mumps vaccine (preferably combination measles, mumps and rubella) on or after their first birthday or other evidence of immunity. The 2 doses of vaccine should be at least 4 weeks apart. When interpreting overseas vaccine documentation, clinicians must note whether the patient received measles vaccine only or the trivalent MMR. A written or verbal report of a history of measles (as well as mumps and rubella) disease is not considered adequate documentation of immunity. While serologic confirmation is acceptable, RHAP should administer MMR to any refugee in need of immunization with any of the three disease components. Most refugees will need a dose of MMR for coverage against rubella and/or mumps. Thus MMR may need to be given even if a refugee has documentation of previous measles vaccination. NOTE: Administration of measles vaccine (M) or measles/rubella vaccine (MR) may be documented on overseas records. These records should be carefully reviewed and doses appropriately documented to assure appropriate follow-up. HEPATITIS B: HBV vaccine is now being used in much of the world. Schedules may vary slightly from ACIP guidelines. In general, the minimum interval between dose 1 and dose 2 is 4 weeks and between dose 2 and 3 is 8 weeks. The final (third or fourth) dose in the HBV vaccine series should be administered no earlier than age 24 weeks and at least 16 weeks after the first dose. When using combination vaccines that include HBV, four doses are recommended. Lastly, individuals who have received one or two doses of vaccine overseas and then have a positive Anti-HBs serology test during RHAP still should finish the remaining doses of the HBV vaccine series. VACCINES FOR RHAP clinicians should follow all routine or catch-up CHILDREN recommendations of the ACIP/MDPH Immunization Program. These recommendations include immunization against hepatitis B, polio, diphtheria, tetanus, pertussis, H. influenzae type B, measles, mumps, rubella, pneumococcus, and varicella as well as the newer recommendations for human papilomavirus, rotavirus, hepatitis A, meningococcus, and influenza. Review current ACIP/MDPH Immunization Program recommendations  HYPERLINK "http://www.mass.gov/eohhs/gov/departments/dph/programs/id/immunization/guidelines-and-schedules.html" for routine and catch-up vaccination of children and adults and  HYPERLINK "http://www.mass.gov/eohhs/gov/departments/dph/programs/id/immunization/school-requirements.html" requirements for school attendance. A note on repeating immunizations: Some clinicians may be concerned that it is unnecessary to re-immunize children (or adults) who do not have documentation of prior vaccination. ACIP recommendations state that while various approaches are valid, repeating vaccinations is an acceptable option that is safe and prevents the need to obtain and interpret serologic tests. If avoiding unnecessary injections is desired, judicious use of serologic testing might help determine which vaccinations are needed; however, since for some vaccines, the most readily available serologic tests cannot document protection against infection, it is RHAP policy that serologic testing be limited to determining immunity to Hepatitis B and Varicella. Most refugees will be under-immunized for most vaccines and lack documentation for those they did receive. Given school and USCIS requirements, clinicians should promptly vaccinate refugee children with all needed age-appropriate vaccines. For ascertaining the need for varicella immunization, RHAP protocols include a mixed screening strategy to ensure immunity in all refugees. Such a screening strategy has been shown to be cost-effective for varicella. Clinicians should assess for a reliable history of chicken pox disease. If the patient has had chicken pox, the clinician should document the positive history on the RHAP form. In addition, if the clinician notes signs of chicken pox scars on physical examination, s/he should document this on the form. In these cases, no immunization is needed. Additionally, refugees 5 years of age and older will be screened for anti-varicella IgG antibody levels at the first visit. This age was determined based on seroprevalance studies as noted above and RHAP administrative requirements. Those with serologic evidence of immunity do not need immunization while those without immunity should receive the vaccine and be instructed on follow-up timing if a second dose is needed. Clinicians may also opt to give a single dose of vaccine to school-aged children pending the serology result to facilitate school entry. Children under age 5 years without a positive history or physical exam should receive the vaccine without serologic testing. The revised RHAP form contains space for documentation of the results of varicella serology. For measles, all refugees should receive MMR vaccine according to ACIP/MDPH Immunization Program schedules. Refugees born in or after 1957, who are age 12 months or older and without contraindications, should be given the first dose of MMR vaccine at the first visit. This dose will also cover for immunity to rubella. For children (and adults who meet ACIP criteria), a second dose of MMR at least 4 weeks after the first dose is recommended to ensure measles and mumps immunity. Remember, children vaccinated against measles before their first birthday should be revaccinated if they are now >12 months of age. The 2nd dose may be given at age 4-6 years, prior to school entry, provided >4 weeks have elapsed. Child Vaccine Updates Recent updates in child and adolescent vaccines are summarized as follows: Rotavirus vaccine is recommended in either a 2-dose schedule at ages 2 and 4 months (Rotarix) or 3-dose schedule at ages 2, 4, and 6 months (RotaTeq). The first dose should be administered at ages 6 weeks through 12 weeks with subsequent doses administered at 4--10 week intervals. Rotavirus vaccination should not be initiated for infants aged 14 weeks 6 days and the maximum age for the final dose is 8 months 0 days The human papillomavirus (HPV) vaccine is recommended in a 3-dose schedule with the second and third doses administered 1-2 and 6 months after the first dose. Routine vaccination with HPV is recommended for all adolescents aged 11-12 years; the vaccination series can be started as young as age 9 years; and a catch-up vaccination is recommended for females aged 13-18 years who have not been vaccinated previously or who have not completed the full vaccine series. Males aged 11-18 may also be immunized regardless of individual risk. Either HPV4 (Gardasil) or HPV2 (Cervarix) can be used for females; only HPV4 is approved for males. Hepatitis A vaccine consists of a 2-dose schedule with the 2nd dose administered 6-18 months apart. It is recommended for all children 12-23 months of age, but it may be completed after 23 months of age if necessary. NOTE: In recognition of research that has shown high levels of naturally-acquired immunity to hepatitis A virus, until it becomes a school entry requirement, RHAP will NOT require clinicians to administer hepatitis A vaccine during the health assessment. Meningococcal vaccination is routinely recommended. The MCV4 vaccine should be given to children 11-12 years of age with a booster dose at 16 years of age. In addition, unvaccinated adolescents at any age should receive one or two doses as appropriate. Certain high risk individuals should also receive a 1 or 2 dose primary series of MCV4 (e.g., asplenia, persistent compliment component deficiencies, HIV infection, military, travel, etc). Boosters may be indicated if they remain at risk and should be given at >3 year intervals for children aged 2 through 6 years and at > 5 year intervals for persons aged 7 years and older. See the  HYPERLINK "http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html" ACIP recommendations on meningococcal vaccines for more detailed information. Tdap. Tdap is routinely recommended for all adolescents at 11-12 years and can be administered, regardless of the interval since the last tetanus- or diphtheria- containing dose (no minimum interval). Children aged 7-10 years who are not fully immunized with the DTaP vaccine (<5 doses or < 4 doses if the 4th dose was given on or after the 4th birthday) should be given Tdap vaccine as the first dose in the catch-up series. Adolescents 11-18 years of age who have not received a Tdap should be given one at their 1st visit. In addition, a single dose of Tdap should be given to all adolescents who will be close contacts with infants to help prevent transmission of pertussis. Pneumococcal Vaccines. PCV13: This vaccine series is recommended routinely for healthy children through 59 months of age. It is recommended for PCV13 nave children with chronic medical conditions through 71 months of age (e.g., chronic heart disease, chronic lung disease [including asthma if treated with high dose steroids], diabetes, immunocompromsing conditions, asplenia (including sickle cell), cochlear implants; and cerebrospinal fluid (CSF) leaks, etc.). In addition, a single dose of PCV13 is recommended for children 6 through 18 years of age who have never been vaccinated with: functional or anatomic asplenia; HIV infection or other immunocompromising conditions; cochlear implants; and CSF leaks. PPSV23: 1 dose is also recommended for children >2 years of age with certain chronic medical conditions including, asplenia, immunicompromising conditions, cochlear implants and CSF fluid leaks. One-time revaccination >5 years after the 1st dose is indicated for those with: functional or anatomic asplenia (including sickle); HIV infection or other immunocompromising conditions; chronic renal failure or nephrotic syndrome. See the ACIP immunization schedules for  HYPERLINK "http://www.cdc.gov/vaccines/schedules/index.html" guidance on risk groups, revaccination and intervals between doses of PPSV23 and PCV13. See also the  HYPERLINK "http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html" ACIP recommendations for pneumococcal vaccines for more detailed information. VACCINES FOR Td/Tdap: ADULTS All adults lacking a completed primary series of diphtheria and tetanus toxoid should be vaccinated with three doses of Td. The first dose of the series should be Tdap vaccine. The first two doses of a primary series should be administered during health assessment visits, after which the refugee should receive subsequent doses by a primary care provider or at a third visit with the RHAP clinic. There is no need to repeat doses if the schedule for the primary series or booster doses is delayed. A single dose of Tdap should be administered to all adults who have not previously received one, regardless of the time since the last tetanus- or diphtheria- containing dose (no minimum interval). Tdap should replace Td for a single dose in the primary series for unvaccinated or partially vaccinated adults or for a booster dose if they have completed the series. Special note for pregnant women: Tdap should be administered during each pregnancy, regardless of the time since last dose of Td or Tdap (no minimum interval) To maximize antibody transfer to the infant, administer Tdap between 27 and 36 weeks gestation, although Tdap may be given any time during pregnancy. To help prevent the transmission of pertussis to infants, all adolescent and adults who are close contacts should receive a single dose of Tdap. Children < 7 years age should be up-to-date on their DTaP series. This is referred to as the cocooning effect to protect infants until their own immunity develops. All RHAP clinical staff should receive a booster dose of Tdap regardless of interval since the last Td dose. For adults who have not received the primary series of at least 3 doses of DTP or TD/Td/Tdap, vaccinate as follows: DoseAge/IntervalProduct Primary 1---TdapPrimary 24 - 8 weeks after #1 doseTdPrimary 36 - 12 months after #2 dose TdBoosterEvery 10 years since last doseSingle dose of Tdap if not received, and then Td POLIO: Routine vaccination is not recommended for persons over age 18 years who reside in the United States except for individuals at high risk of exposure to wild-type polio virus and unimmunized adults at risk of exposure to OPV. Unimmunized adults who require vaccination should receive three doses of IPV per the above schedule for Td. MMR: Adult refugees born in or after 1957 should have documentation of having received at least one dose of live measles vaccine, as MMR with mumps and rubella, on or after their first birthday, or serologic evidence of immunity. If not, proceed to vaccinate them with MMR. A second dose of MMR for measles and mumps coverage is recommended for adults who: are recently exposed to measles/mumps cases or have been in an outbreak setting were previously vaccinated with killed measles vaccine were vaccinated with an unknown vaccine between 1963 and 1967 are students in post-secondary educational institutions work in health care facilities plan to travel internationally Because of the high potential for contact with new immigrants or international travelers by refugees, the RHAP recommendation is two doses of MMR for susceptible adult refugees for whom measles/mumps vaccination is indicated. MMR doses may be given at an interval of one month apart, with the first two doses of Td/Tdap in the above schedule. MMR is contraindicated during pregnancy. Routine pregnancy testing before administering live vaccines is not recommended. According to the ACIP, reasonable practices include: Asking women if they are pregnant or might become pregnant in the next 4 weeks; Not vaccinating women who state they are pregnant or plan to become pregnant; Explaining the theoretical risk to the fetus if MMR or varicella vaccine is administered to a pregnant woman; and Counseling women who are vaccinated not to become pregnant during the 4 weeks after receiving MMR or varicella vaccine. All RHAP clinical staff should have documented immunity to measles, mumps and rubella, or receive 1 dose if MMR if born before 1957 or 2 doses of MMR if born in or after 1957. HEPATITIS B VIRUS (HBV): Adults should be vaccinated for HBV if they fall into a high-risk category, come from a country where hepatitis B is intermediately or highly endemic (HBsAg prevalence >2%), or are a household contact. The first dose should be given whenever possible at the first visit. The need for subsequent doses is determined after interpretation of results of Anti-HBs and HBsAg serologic tests. Individuals who received one or two doses of vaccine overseas and then have a positive Anti-HBs antibody test during RHAP should still finish the full three-dose vaccine series. HEPATITIS A VIRUS: Vaccination of adults is based on personal risk criteria. As noted for children, most adult refugees will be immune to hepatitis A virus from naturally acquired infection. INFLUENZA: All refugees and RHAP clinical staff without contraindications should have a seasonal dose of flu vaccine. PNEUMOCCOCUS: PPV23: 1 dose of PPV23 should be administered to all adults 65 years of age or older; younger adults with chronic medical conditions including asthma; and those who smoke cigarettes. One-time revaccination >5 years after the 1st dose is indicated for adults 19 through 64 years of age with: functional or anatomic asplenia (including sickle cell); HIV infection or other immunocompromising conditions; chronic renal failure or nephrotic syndrome. No further doses are needed for those vaccinated at > 65 years PCV13: A single dose of PCV13 is recommended for adults who have never been vaccinated with: functional or anatomic asplenia; HIV infection or other immunocompromising conditions; cochlear implants; and CSF leaks. See the latest ACIP immunization schedules for  HYPERLINK "http://www.cdc.gov/vaccines/schedules/index.html" guidance on risk groups, revaccination and intervals between doses of PPSV23 and PCV13. See also the  HYPERLINK "http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html" ACIP recommendations for pneumococcal vaccines for more detailed information. VARICELLA-ZOSTER: All adult refugees should be assessed for immunity to varicella by history, exam, and serologic testing as described above. Susceptible individuals require two doses of the varicella vaccine, given at least 4 weeks apart. The first dose should be initiated at the second RHAP visit. Varicella vaccine is contraindicated during pregnancy. When giving MMR and varicella vaccines to women of child bearing age, the patient should be advised to avoid getting pregnant for one month after vaccination. For all adults 60 years of age and older, zoster vaccine should be given to prevent shingles unless the patient has specific medical contraindications. Refugees in this age group may be immunized for zoster. Screening for a history of varicella or serologic testing is not necessary or recommended. Titers consistent with immunity to chickenpox may represent waning immunity that is not sufficient to prevent zoster. NOTE: because of the complexities of Medicare reimbursement, RHAP recognizes that clinical sites may not be able to provide Zostavax to refugees during the RHAP. RHAP sites can be reimbursed for zoster vaccine administered during the health assessment. All RHAP clinical staff should have documented immunity to varicella. HUMAN PAPILLOMAVIRUS: Vaccination is recommended for females aged 11-26 years who have not been vaccinated previously or who have not completed the full vaccine series. Males aged 11-21 should also be immunized regardless of individual risk. Males aged 22-26 years should be immunized based on risk. MENINGOCOCCAL: Vaccination of adults is based on personal risk criteria, including first year college students living in dormitories. Certain high risk individuals should also receive a 1 or 2 dose primary series of MCV4 (e.g., asplenia, persistent compliment component deficiencies, HIV infection military, travel, etc). Boosters may be indicated if they remain at risk and should be given at > 5 year intervals for persons aged 7 years and older. Use MPSV4 vaccine, if patients are 56 years of age or older. See the latest ACIP immunization schedules for  HYPERLINK "http://www.cdc.gov/vaccines/schedules/index.htm" guidance on risk groups, recommendations for primary series and need for boosters. See also the HYPERLINK "http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html"ACIP recommendations on meningococcal vaccines for more detailed information. MDPH will reimburse clinics for additional nurse visits and vaccine costs as part of RHAP for adults who need to complete a primary vaccine series, for example a second or third dose of Td, Hepatitis B, HPV or varicella vaccines. The purpose of this policy is to facilitate completion of age-appropriate immunization of adults in a timely manner in anticipation of the refugee applying for adjustment of legal status, i.e. a green card. For insured refugees, clinics should seek reimbursement for visits from the patients insurance; therefore, clinics will generally not need to utilize this reimbursement mechanism for insured refugees who continue to receive primary care at their site. The policy, however, provides a mechanism for sites to seek reimbursement for a vaccine office visit for uninsured refugees or refugees who were seen for the RHAP but receive primary care elsewhere and do not have PCP authorization for the visit. These visits must occur within one year of the refugees date of entry in the United States. Further information on this policy is available from the RHAP Coordinator at 617-983-6564. Pregnant Women MMR, varicella, zoster and LAIV are the only routine, live viral vaccines given in the U.S. those are contraindicated during pregnancy. All other routine vaccines (and TB skin testing) may be given to pregnant women who are at risk of exposure. There is no apparent risk of adverse effects to developing fetuses when hepatitis B vaccine is administered to pregnant women. The vaccine contains non-infectious HBsAg particles and should cause no risk to the fetus. Therefore, the vaccine series can be administered to women who are at risk and who test negative for hepatitis B virus infection. Refugee women of reproductive age should be questioned about being pregnant or having intentions of getting pregnant before administering MMR or varicella vaccine and counseled as noted above. Although a theoretical risk of congenital rubella syndrome exists for fetuses of pregnant women vaccinated with MMR, no harm to a fetus has been documented in women inadvertently vaccinated during pregnancy. Routine pregnancy testing before administering live vaccines is not recommended. According to the ACIP, reasonable practices include: Asking women if they are pregnant or might become pregnant in the next 4 weeks; Not vaccinating women who state they are pregnant or plan to become pregnant; Explaining the theoretical risk to the fetus if MMR or varicella vaccine is administered to a pregnant woman; and Counseling women who are vaccinated not to become pregnant during the 4 weeks after receiving MMR or varicella vaccine. Providers assessing pregnant women should administer influenza vaccine to all women who will be pregnant during influenza season, regardless of stage of pregnancy. Administration of influenza vaccine is considered safe at any stage of pregnancy. Tdap should be administered during each pregnancy, regardless of the time since last dose of Td or Tdap (no minimum interval). To maximize antibody transfer to the infant, administer Tdap between 27 and 36 weeks gestation, although Tdap may be given any time during pregnancy. Pregnant women who have never received Td or have not completed the 3-dose primary series should be vaccinated. Tdap should replace one dose of Td, preferably between 27 weeks and 36 weeks.Women not vaccinated with Tdap during pregnancy should receive a dose immediately post partum. To reduce the likelihood of transmitting pertussis to infants, all adolescents and adults who are close contacts of infants, and have not already received a Tdap, should receive a single dose. Immune globulin or a specific immune globulin is indicated for pregnant women following exposure to measles, hepatitis A or B, tetanus, chickenpox, or rabies. Lastly, clinicians may also perform urine HCG testing at either RHAP visit.  HYPERLINK "http://www.cdc.gov/vaccines/pubs/preg-guide.htm" Full recommendations for pregnant and breastfeeding women can be found at CDCs Guidelines for Vaccinating Pregnant Women. Contraindications History of anaphylactic or anaphylactic-like reactions to vaccine components and the presence of moderate or severe illness, with or without fever, are contraindications applicable to all vaccines. For the purposes of the RHAP, the patients immunization series will be considered incomplete and he/she should be referred to primary care for consideration of allergen desensitization and follow-up on diagnosed illnesses. TB Testing and The TB test (interferon gamma release assay [IGRA] or Vaccination tuberculin skin test [TST]), varicella vaccine, and MMR vaccine may be given on the same day. If MMR or varicella vaccines have been given recently, postpone the TB test until 4-6 weeks after administration of the vaccines because such vaccination may temporarily suppress tuberculin reactivity and affect IGRA test results. U.S. Citizenship and All refugees who apply for adjustment of status to permanent Immigration Service resident (legal permanent residence, or green card) are Requirements for required to have written documentation of vaccination or Adjustment of immunity for all vaccines recommended by the ACIP based on Status to Permanent the age of the individual at the time of medical evaluation (with Resident the exception of HPV and zoster). This documentation is verified by a Civil Surgeon, a physician appointed by the USCIS District Office to complete medical evaluations of adjustment of status applicants. Refugees are eligible to apply for permanent residence one year after arrival in the United States. The  HYPERLINK "http://www.cdc.gov/immigrantrefugeehealth/exams/ti/civil/vaccination-civil-technical-instructions.html" \l "tbl1" immunization requirements apply to all refugees, not just children. The immunization guidelines require all applicants to have documentation of immunity to, or primary vaccination against, all major vaccine-preventable diseases. In addition, the USCIS requires seasonal influenza vaccine for eligible individuals age 6 months to 18 years and > 50 years. Single booster doses for adults are considered incomplete and may cause delay or jeopardize granting of legal permanent residence status. Varicella requirements may be met by vaccination, reliable written or oral history of varicella disease, or serologic evidence of immunity. While waivers exist for some incomplete vaccine series (such as insufficient time to complete a series, or medical contraindication), RHAP providers are strongly encouraged to support appropriate and complete vaccination of refugee patients. RESOURCES HYPERLINK "http://www.mass.gov/eohhs/gov/departments/dph/programs/id/immunization/"Immunization Program Massachusetts Department of Public Health 617-983-6800  HYPERLINK "http://www.cdc.gov/vaccines/recs/default.htm" CDCs Immunization Program 800-CDC-INFO or 800- 232-4636  HYPERLINK "http://www.cdc.gov/vaccines/recs/default.htm" Recommendations of the Advisory Committee on Immunization Practices HYPERLINK "http://vaers.hhs.gov/index"Vaccine Adverse Events Reporting System (VAERS) 800-822-7967  HYPERLINK "http://www.immunize.org" Immunization Action Coalition 612-647-9009  HYPERLINK "http://www.cdc.gov/immigrantrefugeehealth/guidelines/domestic/immunizations-guidelines.html" CDC Domestic Refugee Health Guidelines: Immunization  Centers for Disase Control and Prevention. Measles United States, January 1-August 24, 2013. MMWR. 2013;62:741-743.  Centers for Disease Control and Prevention. Measles Outbreak Among Members of a Religious Community Brooklyn, New York March-June 2013. MMWR. 2013;62:752.  Centers for Disease Control and Prevention. Measles Outbreak Outbreak Associated with a Traveler Returing from India North Carolina April-May 2013. MMWR. 2013;62:753  Centers for Disease Control. Import-associated measles outbreak -- Indiana, May--June 2005. MMWR. 2005;54:1073-1075.  Centers for Disease Control. Update: multistate outbreak of mumps -- United States, January 1--May 2, 2006. MMWR. 2006;55:559-563.  Centers for Disease Control and Prevention. General recommendations on immunization recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2011;60(No. RR-2):27-29 .  Figueira M, Barnett ED, Christiansen D, McNamara ER. Cost-benefit of serotesting compared with universal immunization for varicella in refugee children from six geographic regions. J Travel Med. 2003;10:203-207.     Updated October 2013 MASSACHUSETTS REFUGEE HEALTH ASSESSMENT GUIDE Section 3: CLINICAL PROGRAM PAGE  Immunizations 3.8. PAGE 1 $9IźŮ|re]TO> hIshi.CJOJQJ^JaJ hi.5h[65OJQJhi.OJQJhRhi.CJOJQJhRCJOJQJheb7CJOJQJhi.CJOJQJhi.5OJQJh5OJQJhU~hU~5OJQJhi8h_5OJQJjh(h_Uhi8h_5CJOJQJaJh_5OJQJhi.5CJ OJQJha5CJ OJQJhj5CJ OJQJ& ,"p@ P !$$/If]gdi8" ,"p@ P !$/]gd ,p@ P !$/mHH- ,p@ P !$/$ ) *@ P !$@ /^@ `gdR& ,p@ P !$`/^``gdU~kkd;$$Ifl#$ t0644 lap ] 3 4 Qhc]c^  ,p@ P !$/ ) Zp@ P !$@ /^@ gdq" ,Zp@ P !$@ /^@ gdU 4 )@ d^@ gdU 4 )dgdU 4# ,Zp@ P !$@ /^@ ` T U V U V W X Y Z [ \ пЦ|gP>|.hU 4B*OJQJmH phsH "hU 4B*H*OJQJmH phsH ,jhU 40JB*OJQJUmH phsH (hU 4hU 4B*H*OJQJmH phsH 2jhU 4hU 40JB*OJQJUmH phsH h,7B*OJQJmH phsH 1hU 4h,7B*CJOJQJ^JaJmH phsH hIsh,7CJOJQJ^JaJ hIshqCJOJQJ^JaJ hIshi.CJOJQJ^JaJhU 4CJOJQJ^JaJ \ ] ` e k z { | 2 4 S } ~  a b νν۳۳۩۳}i}Z}h3h30JCJOJQJ'j;h3h*CJOJQJUjh3CJOJQJUhCJOJQJhICJOJQJh3CJOJQJhFCJOJQJhi.CJOJQJ!jhU 4hq0JOJQJUhU 4hqCJOJQJhqCJOJQJh,7CJOJQJ hU 4h,7CJOJQJ^JaJ"  j n   01<=%ȼȼȼȼȋzn]n jhuP56UmHnHuhuP56mHnHu!hU 4h70J56mHnHu&j<hU 456UmHnHu jhU 456UmHnHuhq'956mHnHuh756mHnHuhU 456mHnHuh5mHnHuh VI5mHnHuhr5mHnHuhi.5mHnHu%&'YZyz()*+CKLMNPQػzcRDR5hvhi.56mHnHuh0J56mHnHu!hhv0J56mHnHu,j>hh56UmHnHuh56mHnHu jh56UmHnHuhv56mHnHuhi.56mHnHuhq'956mHnHuhuP56mHnHu!huPhuP0J56mHnHu jhuP56UmHnHu,j=huPh6a56UmHnHuQRop789:}E$ ) pP !$@ $d%d&d'd/NOPQ^@ a$gd5 ) p@ P !$@ /^@  ,p@ P !$/ QR pCDEF^_`cdԱqbVh0JCJOJQJh^nYhi.0JCJOJQJ'j Bh^nYhPCJOJQJUjh^nYCJOJQJUhvCJOJQJh^nYCJOJQJhCJOJQJh h 0JCJOJQJ'j @h hCJOJQJUjh CJOJQJUh CJOJQJh VICJOJQJhi.CJOJQJ5789DPĺİuuuuhh^UFh'gkCJOJQJmHnHuhi.5OJQJh/CJOJQJh5CJOJQJ\hVb>5CJOJQJ\h55CJOJQJ\h/5CJOJQJ\h3CJOJQJh5CJOJQJhi.CJOJQJhvCJOJQJh^nYCJOJQJh^nYh^nY0JCJOJQJjh^nYCJOJQJU'j]Ch^nYhPCJOJQJUP{ 467+GIJh˷˖ukakW˭h VICJOJQJheb7CJOJQJhnCJOJQJhq'9CJOJQJhVb>CJOJQJhVb>hi.CJOJQJhVb>hx%CJOJQJh$CJOJQJhCJOJQJhFbCJOJQJhvCJOJQJhi.CJOJQJhx%CJOJQJhi.OJQJhi.5OJQJhi.CJOJQJmHnHu6IC01zzz&$$d%d&d'dNOPQa$ ,p@ P !$@ /^@ & F ) p@ P !$/gdM & F ,p@ P !$/ hBC $1 %*01>DHQS⬢⊆~tj`jh#CJOJQJhCJOJQJhrCJOJQJh#hi.hq'9h/hx%CJOJQJhVb>CJOJQJhCJOJQJhMCJOJQJh R%CJOJQJh^nYCJOJQJhCJOJQJhh>*CJOJQJhi.CJOJQJh*CJOJQJh26CJOJQJ%12/0YZ ##T$$$" ,p@ P !D%/]gdR? ,p@ P !D%/] ,p@ P !$@ /^@  ,p@ P !$/  (1IMRW\59FT\f#,-./09:캰⦺{hq'9hi.CJOJQJhMCJOJQJhi9CJOJQJhhOpCJOJQJh CJOJQJh5CJOJQJhrCJOJQJh$CJOJQJh^nYCJOJQJh` CJOJQJhCJOJQJhi.CJOJQJh#CJOJQJ.:;<WZmn!!##$$S$T$j$k$$$$$$$$$%%.%/%0%̿̇̇}s}i_s}RhIs6CJEHOJQJh+[CJOJQJhIsCJOJQJhCJOJQJh3CJOJQJhi.56OJQJhi.EHOJQJh$CJEHOJQJhi.CJEHOJQJhi.5EHOJQJhi.56EHOJQJhi.OJQJhi.CJOJQJhi.CJH*OJQJ,jhq'9hi.0JCJEHH*OJQJU$/% &&!&#&&&"'qNN" & F ,p@ P !$@ /^@  & F ,p@ P !$/ ,p@ P !$@ /^@ ) & F ,Zp@ P !$@ /^@ `gdR?& ,p@ P !D%p/]^pgdR?0%a%b%%%%%%%%%% & & &&!&&&"'#'$'޷zpcYMcB8hKCJOJQJhi.5CJOJQJhi.CJEHOJQJhi.CJOJQJhi.56CJOJQJh3CJOJQJhR?hR?CJEHOJQJhR?hR?6CJEHOJQJhR?hi6CJEHOJQJhR?0JCJEHOJQJ hR?hi0JCJEHOJQJ+j DhR?hiCJEHOJQJU%jhR?hiCJEHOJQJUhR?hiCJEHOJQJ"'#'N)X*****,,-l& & F ,Zp@ P !$/^`" ,p@ P !$@ /^@ gdu gdu & F ,p@ P !$/" & F ,p@ P !$@ /^@ $''((((J)))))))))))N*O*P*S*T*X**********+ά}sf[Sh$hi.5hi.5CJOJQJhi.56CJOJQJh[6CJOJQJ'jEhuhuCJOJQJUhu0JCJOJQJhuhu0JCJOJQJ'jDhuhuCJOJQJUjhuCJOJQJUhuCJOJQJhqCJOJQJh` CJOJQJh$CJOJQJhi.CJOJQJ +++B+E+u+w+y+|+++++++++++++ , ,,S,T,,,,,,,,,̿ѵ̄znf^huhi5huhu5huhu0J56huhu0J5jHhu5Uhuhu0J5mHnHuhuhi0J5huh'G0J5huh+[0J5jGhu5U hu5jhu5U ht=5huht=5huh+[5h+[h$hi.5hi.!,- - -:-;-<-g-n-p---#.).+.B.M.o.q.............%/&/Q/X/Z/X0Y0_0a0d0f0000[1ҹүґ҆{hi.6CJOJQJhi95CJOJQJh/DCJOJQJhuCJOJQJhIsCJOJQJh8[CJOJQJhuh8[CJH*OJQJhi.>*CJOJQJhi.CJOJQJh CJOJQJh h 5CJOJQJhi.5CJOJQJ--g--$.....Q//X0Y0a001111 ) Zp@ P !$/^& & F ,Zp@ P !$/^` & F ) Zp@ P !$/[1i1111112222E3L3M3m3o333333444Q4R4o4p44495B5G5e5ߺߒ{qqqg{qg{g]ghVb>CJOJQJhiCJOJQJhuCJOJQJhuhi.CJOJQJh[CJOJQJhuh[CJOJQJhtUCJOJQJ!huhtUB* CJOJQJphhuhtUCJOJQJh CJOJQJh h 5CJOJQJhi.CJOJQJhi.6CJOJQJhK6CJOJQJ!1222444p5fB$ & F /Z*p@ P !$/^( & F /Z*p@ P !$/^`# & F ,Zp@ P !$^gdu& & F ,Zp@ P !$/^`% & F ,Zp@ P !$/^gdue5f5g5h5i5p5z5555555556G6H6K6M6S6W6^6g6p6r66666ƻФ籚vlbvXlKhuhIsCJOJQJhCJOJQJht=CJOJQJhIsCJOJQJhuh4BCJOJQJh4BCJOJQJhuhtiCJOJQJhtiCJOJQJhuhd2CJOJQJhi.CJOJQJhi.6CJOJQJhiCJOJQJhd2CJOJQJhuhiCJOJQJhx=CJOJQJhx=hi>*CJOJQJp5q5z56677Q9tMMM& & F ,Zp@ P !$/^` ) Zp@ P !$/gdx=% & F ,Zp@ P !$/^gdu$ & F /Z*p@ P !$/^$ & F /Z*p@ P !$/^66666677%838j8o8888&9'9(9<9N9O9P9Q9Ĺ}gWG:hi.6CJEHOJQJh`h`0J6CJOJQJh`hD0J6CJOJQJ*j?Ih`hP6CJOJQJUh`6CJOJQJjh`6CJOJQJUhD6CJOJQJhi96CJOJQJhK6CJOJQJhi.6CJOJQJhi.56CJOJQJ htihIsCJOJQJ^JaJhi.CJOJQJh+CJOJQJhIsCJOJQJQ9R9\9:<<`>a>D?mJ" & F ) Zp@ P !$/1$^& & F ) Zp@ P !$0/1$^`0" & F ) Zp@ P !$@ /1$^@  & F ) Zp@ P !$/1$& & F ) Zp@ P !$/1$^`Q9R9Z9\9_9999:(:):+:::@:B::::::::::*;A;M;a;b;l;;;<<ɽ١مuiiɽ]]]]Yh2Hih1:CJEHOJQJhx=CJEHOJQJhx=h@CJEHH*OJQJhVb>CJEHOJQJhx=h@>*CJEHOJQJh@CJEHOJQJhgwhgw>*CJEHOJQJhgwCJEHOJQJhgwhgw5CJEHOJQJhi.CJEHOJQJhi.5CJEHOJQJhx=5CJEHOJQJ!<=`>a>e>g>C?D?Q?R?S??/@M@N@O@@@@ AAAA̲̿xjxjxZxjHx=hT 5EHOJQJ#hL4~hL4~5CJEHOJQJaJhL4~B*OJQJmH phsH hL4~CJEHOJQJaJ hL4~hL4~CJEHOJQJaJ hL4~hCJEHOJQJaJhL4~CJEHOJQJhCJEHOJQJh5CJEHOJQJhQT6CJEHOJQJhi.6CJEHOJQJhi.56CJEHOJQJhi.5CJEHOJQJ hi.5\hi.D?E?S?AABaBCCqS & F /p@ P !$`'% & F /Zp@ P !$`'@ ^@ gdI." & F /Zp@ P !$`'Z^Z 'd^gdL4~'^`gdL4~) & F ) Zp@ P !$/1$^`gdAAB(BDB]B`BaBfBgBBB C CDnDyDzDDDDDDEEEEEv^L?2hi.5CJEHOJQJh/5CJEHOJQJ#h`hi.0J5CJEHOJQJ.jKh`hP5CJEHOJQJUh`5CJEHOJQJ"jh`5CJEHOJQJUh/hi.5CJEHOJQJ#huPhuP0J5CJEHOJQJ#huPhi.0J5CJEHOJQJ.jNJhuPh6a5CJEHOJQJUhuP5CJEHOJQJ"jhuP5CJEHOJQJUE9EF GGGGGHHIII8KPKKK LLRM[M㶧sfZNB6hCJEHOJQJhdZCJEHOJQJhZsCJEHOJQJhzCJEHOJQJhi.CJEHH*OJQJ(jhx=hi.0JCJH*OJQJUhi.CJEHOJQJ$hShi.CJEHOJQJ^JaJhx=hi.CJEHOJQJhx=h+CJEHOJQJh/hSCJEHOJQJhx=hSCJEHOJQJhx=CJEHOJQJhx=hx=5CJEHOJQJ[MaMeMfMM+N:NFNxNNN8OmOOOOOOPPPPPPPPPPPQQ詵蝑qaVhhOp5EHOJQJhhOphhOp56EHOJQJh@h@CJEHH*OJQJh@h@>*CJEHOJQJh'GCJEHOJQJh@CJEHOJQJh1:CJEHOJQJh_0CJEHOJQJhi.5CJEHOJQJ\h*CJEHOJQJhhOpCJEHOJQJhi.CJEHOJQJhI.CJEHOJQJ-NPPPPEQ\Q]QSs\ & F @ 4P !$gdhOp @ 4P !$@ /^@  @ 4P !$@ /^@ gdI. @ 4P !$/^gdI.! & F ) Zp@ P !$/1$gd@" & F /Zp@ P !$`'@ ^@ QQQ?QDQEQ]Q^QQQQQQQQRRRRRSSSSS S'SyS{SSSSoTqTTT;͋͋pdhzCJEHOJQJhhOphzCJEHOJQJh$CJEHOJQJh39CJEHOJQJh'GCJEHOJQJh@CJEHOJQJhI.hI.CJEHOJQJhI.hhOpCJEHOJQJhhOphhOpCJEHOJQJhI.CJEHOJQJhhOpCJEHOJQJhB`CJEHOJQJ#TTTTTUU$U%U&U.U/U0U2U8U9UAU\UaUfUrU{U}U~UUUUijsdUIhTCJEHOJQJhhOphTCJEHOJQJhhOphhOpCJEHOJQJ$hJhhOpCJEHOJQJ^JaJhTCJOJQJ^JaJhJCJOJQJ^JaJ hJhJCJOJQJ^JaJ!hJCJEHOJQJ\^JaJ'hJhzCJEHOJQJ\^JaJh$CJEHOJQJ\hI.CJEHOJQJ\hzCJEHOJQJ\S~UWWzZ{Z%]&]>]_oR & F x<^xgddZl @ 4P !$^gddZ & F @ 4P !$/gddZ @ 4P !$/gddZ & F @ 4P !$gddZ & F @ 4P !$gdhOp & F & p@ P !$gd$UUUWVXV^V_VVWWWWXXTXUX\XqXXXXXXX Y YYYȸԜ~oo`o`o`oQBohdZhCJEHOJQJhdZh52CJEHOJQJhdZh4BCJEHOJQJhdZhTCJEHOJQJhdZh<>CJEHOJQJhdZh xCJEHOJQJhdZhhOpCJEHOJQJh$5CJEHOJQJhh5CJEHOJQJhCJEHOJQJhhOphhOpCJEHOJQJhTCJEHOJQJhdZhTCJEHH*OJQJYVYWY[YlYYYYYYY)Z*Z+ZYZZZzZ{ZE[F[N[S[[['\\ĵuiZKKKZhdZhCJEHOJQJhdZh/DCJEHOJQJhhOpCJEHOJQJ hdZhe0JCJEHOJQJ%jLhdZCJEHOJQJUhdZCJEHOJQJjhdZCJEHOJQJUhdZheCJEHOJQJhdZhdZCJEHOJQJhdZh<>CJEHOJQJhdZh52CJEHOJQJhdZh4BCJEHOJQJ\\\\\]]#]&]2]<]=]>]?]D]R]S]Z]w]]]]]^!^"^y^೤tftftUtUtDUfU hdZh<>CJOJQJ^JaJ hdZhaCJOJQJ^JaJhooCJOJQJ^JaJ hdZh:#CJOJQJ^JaJh'GCJOJQJ^JaJ hdZhK.CJOJQJ^JaJhdZhK.CJEHOJQJhdZht=CJEHOJQJhdZh$CJEHOJQJhdZh(CJEHOJQJhdZh/DCJEHOJQJhdZh/DCJEHH*OJQJy^z^^^^ _:_S_______________` `"`#`$`3`;`Z``````ппп{jY hdZh'GCJOJQJ^JaJ hdZh<>CJOJQJ^JaJ#hdZha>*CJOJQJ^JaJh'GCJOJQJ^JaJ#hdZhK.5CJOJQJ^JaJ#hdZhK.>*CJOJQJ^JaJ hdZhK.CJOJQJ^JaJ hdZh:#CJOJQJ^JaJ hdZhaCJOJQJ^JaJhooCJOJQJ^JaJ"__aacbdbc,cocoV @ 4P !$/^gdT  & F  @ 4P !$/ <gddZl x<^xgddZl & F  @ 4P !$x/^xgddZ & F x^xgddZlx^xgddZl````aa%a8a;a?aIaRapaqaaaaaaaaaueuWF8heCJOJQJ^JaJ hdZhaCJOJQJ^JaJhCJOJQJ^JaJhZhi.5EHOJQJ^J hdZhK.CJOJQJ^JaJh8[CJOJQJ^JaJhooCJOJQJ^JaJhrCJOJQJ^JaJ hK.h'GCJOJQJ^JaJh'GCJOJQJ^JaJ#hdZh'GCJH*OJQJ^JaJ hdZh'GCJOJQJ^JaJhdZCJOJQJ^JaJaab b b`babbbcbdbhbmbqbrbbbbbbcc||j|Rj?j|$hehe0JCJOJQJ^JaJ/jNheh6aCJOJQJU^JaJ#jheCJOJQJU^JaJheCJOJQJ^JaJh3CJOJQJ^JaJhK.CJOJQJ^JaJ hdZhK.CJOJQJ^JaJ$hdZhK.0JCJOJQJ^JaJ)jMhdZCJOJQJU^JaJhdZCJOJQJ^JaJ#jhdZCJOJQJU^JaJcc#c+c,c2cncoccc(e*e>eEeUeeeeeezlz[M h/hCJEHOJQJ^Jh.4CJOJQJ^JaJhECJOJQJ^JaJ&h/h35>*CJOJQJ^JaJ h.4h3CJOJQJ^JaJh3CJOJQJ^JaJ h/hCJOJQJ^JaJ#h/h5CJOJQJ^JaJh39CJEHOJQJhjCJEHOJQJht=CJEHOJQJhCJEHOJQJhhOphhOpCJEHOJQJgggggghh`hhhjhkhhhhhiii iiEi[itiiii䞺}p}c}XMXh395CJOJQJhi.5CJOJQJh/5CJEHOJQJh395CJEHOJQJh39hhOp5CJEHOJQJ h.4h/DCJEHOJQJ^JhBCJEHOJQJ^Jht=CJEHOJQJ^Jh/CJEHOJQJ^JhPfCJEHOJQJ^Jh$CJEHOJQJ^Jh/DCJEHOJQJ^Jhi8hCJEHOJQJ^JiijjjjjmkdO$$Ifl F x`(#     0     4 la4 yti9 & F$Ifijjjjjjjjjjjjl"lll4m5mUm_mmmmmmm(o1o:oBoCoLoooooopCpph hi.CJEHOJQJh39hi.5CJEHOJQJh2CJEHOJQJh CJEHOJQJh^m^CJEHOJQJhi.5CJEHOJQJhi.CJEHOJQJhoeCJOJQJh xCJOJQJh^m^CJOJQJhi.CJOJQJhi.6CJOJQJ'jj$j>jAjwmmm & F$IfkdP$$Ifl F x`(#     0     4 la4 yti9AjBjLjijljwmmm & F$IfkdQ$$Ifl F x`(#     0     4 la4 yti9ljmjujjjwmmm & F$IfkdFR$$Ifl F x`(#     0     4 la4 yti9jjjjlw]C) & F @ 4P !$ /^  & F @ 4P !$@ /^@  & F @ 4P !$/^kd S$$Ifl F x`(#     0     4 la4 yti9ll$l4mmmnLnnnnoppqhq & F @ 4P !$x/^xgdK & F @ 4P !$ /^  & F @ 4P !$ & F @ 4P !$ ^  & F @ 4P !$@ /^@ Cpppsss ssssssts|sstQuSufuuvvvv,vCvvvvvvvfvYh[65CJEHOJQJhqwhqw5CJEHOJQJhqwCJEHOJQJh39h39CJEHOJQJh xCJEHOJQJh39CJEHOJQJhL4~CJEHOJQJhq2CJEHOJQJh395CJEHOJQJhi.5CJEHOJQJhe5CJEHOJQJhi.CJEHOJQJhKCJEHOJQJhqqRrsssRuSufuvvvvvt & F @ 4P !$ /^ gd39 & F @ 4P !$ /^  & F @ 4P !$@ /^@  & F @ 4P !$ /^ gdK & F @ 4P !$x/^xgdK vvxxrysyCJEHOJQJ\hIsCJEHOJQJ\h8[CJEHOJQJ\h =F5CJEHOJQJ\"hpnPh =F5CJEHOJQJ\h =FCJEHOJQJ\h39h39CJEHOJQJ\hJhJCJEHOJQJ\˂ ΃σ}~~ @ ^@ gd/@ ^@ gd/l & p@ P !$@ /@&^@ gd/% & F + p@ P !$ /^ gd/ @ 4P !$@ /^@ gd =F (9:;xyz̃̓΃σӃ؃܃݃,-.seseSe;S/jVheheCJOJQJU^JaJ#jheCJOJQJU^JaJheCJOJQJ^JaJh/CJOJQJ^JaJhhOph52CJEHOJQJ h/h 0JCJEHOJQJ%jUh/CJEHOJQJUh/CJEHOJQJjh/CJEHOJQJUh CJEHOJQJheCJEHOJQJh<>CJEHOJQJhCJEHOJQJ.\]|}~yͿ}n_PA3hMhi.EHOJQJ]hX'5CJEHOJQJ\h25CJEHOJQJ\hK5CJEHOJQJ\hq25CJEHOJQJ\"h/hn5CJEHOJQJ\hn5CJEHOJQJ\h/5CJEHOJQJ\"h/hM5CJEHOJQJ\h/CJOJQJ^JaJheCJOJQJ^JaJ#jheCJOJQJU^JaJ$hehe0JCJOJQJ^JaJss/D ,p@ P !$@ $d%d&d'd/NOPQ^@ gdMH$ & pP !$@ Z$d%d&d'd/NOPQ^@ `Za$gdOq!D$ & pP !$@ $d%d&d'd/NOPQ^@ a$gd/9MNhxiiii & F @ 4P !$x/^xgdrj & F @ 4P !$ /^ gdrj ,p@ P !$@ /^@ " ,p@ P !$@ /^@ gd/ ,p@ P !$/ $+,-9BTZ]^IZqr˿whZh3CJOJQJ^JaJh35CJOJQJ^JaJhZCJEHOJQJhrjCJEHOJQJht=CJEHOJQJhBCJEHOJQJh/CJEHOJQJhECJEHOJQJhi.CJEHOJQJhi.5CJEHOJQJhi.5EHOJQJhi.56EHOJQJ]h56EHOJQJ]!"ӓw ,p@ P !$/gd/ @ 4P !$ /^ gd$ @ 4P !$@ /^@ gd$ @ 4P !$@ /^@ gd/ ,p@ P !$@ /^@ '5RW^hk !"ϗui]OC7hi.CJEHOJQJhi8hCJEHOJQJh$CJEHOJQJ^JhCJEHOJQJh$CJEHOJQJ h/h$CJOJQJ^JaJ h/hi8hCJOJQJ^JaJhUCJOJQJ^JaJhZCJOJQJ^JaJht=CJOJQJ^JaJhECJOJQJ^JaJh3CJOJQJ^JaJ#h/hZ5CJOJQJ^JaJ h.4hZCJOJQJ^JaJӓԓՓ)01Ndnݔޔ̶إxl]OD8Dhi.CJEHOJQJhi.5EHOJQJhi.56EHOJQJ]h/h/CJEHOJQJheCJEHOJQJ hZhZ0JCJEHOJQJh80JCJEHOJQJhB-,0JCJEHOJQJ hZh 0JCJEHOJQJ+jWhZh5`VCJEHOJQJUhZCJEHOJQJjhZCJEHOJQJUh/CJEHOJQJh`(ZCJEHOJQJӓԓޔKLږeT & F Z@ 1$^@ ) p@ P !$@ /^@ gdq2 ) p@ P !$/gdq2 ,p@ P !$@ /^@  ,p@ P !$/" ,p@ P !$@ /^@ gd/ ޔKLZ]`ٖږHIʗ<=>Qtk^tVhi.69]h2569CJ\]h26CJ]h2569CJ]hi.569CJ] hi.9hMh`(Zhi.hI.CJEHOJQJhq25EHOJQJhq256EHOJQJ]hq2CJEHOJQJhi.5EHOJQJhi.56EHOJQJ]hi.5CJEHOJQJhi.CJEHOJQJ>ؘsT ,p@ P !$@ /^@ " ,p@ P !$@ /^@ gd  ,p@ P !$/gd  ,p@ P !$/ ,p@ P !$/ @ 4P !$/ QRĘ֘טؘ٘"$,-5yzǼuh]LAA]Lh 56OJQJ!hL4~hL4~56CJOJQJ]h CJOJQJ]hi.56CJOJQJh2h2CJOJQJ]h25CJOJQJ]h25OJQJ]h2CJOJQJ]hi.5OJQJ]hi.56OJQJhL4~56OJQJ.h#%hi.569CJ\]aJmH nH u h#%h2569CJ]aJhi.569]mH nH uz;<=VWXx./8ELRS`iyxm`````h hi.CJOJQJhi.6CJOJQJh h >*CJOJQJhzhz0JCJOJQJ'jXhzh" _CJOJQJUhzCJOJQJjhzCJOJQJUhi.CJOJQJh CJOJQJh2CJOJQJh2CJOJQJ]h CJOJQJ]h 56OJQJ ϝ>?SW'(VWaŹp_ShCJEHOJQJ hp`[hi.0JCJEHOJQJ+jZh`(ZhPCJEHOJQJUh`(ZCJEHOJQJjhp`[CJEHOJQJUhi.5EHOJQJhI.CJEHOJQJhi.CJEHOJQJhi.CJOJQJh CJOJQJh h2HiCJOJQJh hi.CJOJQJh h CJOJQJ)S`a؟ٟ[\àĠ  @ 4P !$@ /^@ gd/ @ 4P !$@ /^@ gdp`[ @ 4P !$@ /^@  @ 4P !$/ @ 4P !$@ /^@ gdI.abŸƟΟן؟ٟڟYZ[\]㰤㤘scWh`(ZCJEHOJQJjhp`[CJEHOJQJUhhjCJEHOJQJ+j\hh6aCJEHOJQJUhjCJEHOJQJhCJEHOJQJhi.CJEHOJQJ hh0JCJEHOJQJ+j-[hh6aCJEHOJQJUhCJEHOJQJjhCJEHOJQJUàĠŠ ټzkaWIWjh+CJOJQJUh+CJOJQJhCJOJQJhp`[hi.0JCJOJQJ'j]hp`[h98CJOJQJUhp`[CJOJQJjhp`[CJOJQJUhi.CJOJQJhCJEHOJQJhi.CJEHOJQJ hp`[hi.0JCJEHOJQJjhp`[CJEHOJQJU+j\h`(ZhPCJEHOJQJU 3Ң|x<sfY $L^`La$ L^`LgduQ$LEƀ^`La$gdU 4$L^`La$gdq$L^`La$gdU 4 @ 4P !$@ /^@ gd1:  !2345âĢѢҢӢԢijno|}~ubUhXhi9CJOJQJ$jhXhi9CJH*OJQJU *hU 4hi9CJOJQJhi96CJOJQJhi9hU 4hi96CJOJQJhU 4hi9CJOJQJhi9CJOJQJjhi90JUh1:h+CJOJQJh+h+0JCJOJQJjh+CJOJQJU'jU^h+h*CJOJQJUأڣޣߣ%&127:aeklnovwxyz¤ä麬韌{r{r{huhi90J* hi90J*hi99EHOJQJ%jhi99CJEHH*OJQJUhU 4hi9CJOJQJh*hi96CJOJQJh*hi9CJOJQJ$jh*hi9CJH*OJQJUhi9hi96CJOJQJhi9CJOJQJhXhi9CJOJQJ,äΤФ 9<= (:sɼl[J hi96CJOJQJ]^JaJ hi96CJOJQJ]^JaJ&h Owhi96CJOJQJ]^JaJjhkrUhkrhi9OJQJhi9CJOJQJhx=hi96CJOJQJhx=hi96CJOJQJ]hx=hi9CJOJQJ,jhx=hi90JCJEHH*OJQJU hi90J*6huhi90J*6 hi90J*huhi90J* t !8"(#]gd[s :&P#$0$gd[sh]h &`#$gd4q $&dPa$ &dPgdvstݺ}qm`h1:h+CJOJQJhkrhk|CJOJQJaJhqhqCJOJQJaJ%jhqhqCJOJQJUaJhi9CJOJQJaJh.Zhi9CJOJQJaJ$h4qhi90JCJOJQJ^JaJ hi90Jjhi90JUhi9hi95CJOJQJ&hk]|hi96CJOJQJ]^JaJ @ 4P !$@ /^@ gd1:;0P:p4q/ =!"#$% Dp;Dd 00  # A":;==;71o)3cs:D@=k:;==;71o)3cX ;lWx9:x}oL[׶纺o̜4H%>DTD@bVT j >r}jmzޒ+qN%(um܆$ a ̬uz||}̟$`k ~?nm ߂WC(~[ߢ 5}} }QG 봟%`0 `0 `0 `0 `0 `0 `0 `0 `0 `0 `0 `0 `0 `0 `0 `0 `0 `0 a5?L k`0 vk.c?'/a+Umv:a.Ή>p+H9K_rV~<+sf=۵+a3u0}+`0 ۭƏ%mag'`0^(*(Oa0aQ‹|NXJLsmNįP ir@">s`0 UCyPW]Ey }D˛rӄ9N6'p/vUM`0 ۭ)|Vԋw`hpi:E .h̎smz| aO!¤+`0 Sn:#q/cS~,: ]h.[&!>OMQyZ -#9xb aR,^X!88F6{kQ6 bkBXJL|Gȍ/CAu4;DãyvS SCpզnC-(N5^xu|FOLJG= f[vJF64I}I<Є|ta =gdv U@|"qynoL JYP Z'PNCGa5Kؿ^(9AW->1N >\a @>P$fru킐G`nWlq.BOl79n:y+rG!Nu t }ieKdz{>|Y>Bon"u\_^xy!Qت8^~8""2">=2CSE>N_klsV$B)}Lc ~tϡ} 㯃ja1kЏ·="uޛHBW)7|AYA(oGbl8ř%:e*іa`0u' k;wÝIo,) _=7xd~G9"3o> #\!Mp!x C.vg, j ./}T s' K`9}lvlԕqc;V{ٷ=`K%?od[\qaa3^9R4at_ޖRw̿8  Ϡ2"20l㾜8n'8V\ BkWtm,@JJ~>-BN #8GvCcI1$~LRS\n>O>mNw2 X_l ^O%hh Gkf'Y6HYzx 6maV{FrBߋ@tbkB=8$殰]DZ%|؎x}n#[ ND@"q\q}&zD>IZE"' ^@{^<8=SwQLSb_ wQ*MmB~%Ŗ(P|-(9`Γt"'D XpU0Ԡޟ镹]֎Aؤ(zUY 2Atهl+^8r ѩKҞhE~6DΪO"M/Pwr-WHﺊh?b1g3慇Pi)``l˲.X~V{6q\ mTB]}-y+g+q q+:Pr%_UH|:<u=jm+{D81S$ "^`9F<yO!`0pL!*?ixW1#wT;Ī-2Nm_8.G[JLR]&OXLɽ6(PW)ڲS){s5NЁ {dp^;x٪\nV`V'wbi6/Y7Os|7ǓkXR ji1//ڿ#r㷼9'0+@Rg=)c#ZuA(<C^I9@܀c>cqȯH:}'hk|8PpOL3iY?ZTM 9 TܧG|Fi_Q@5E#%\$8xnb;R ބ?14gkb/:.w0=~I[BV,iJ+c8lpYAvؗ=p;z?s7HQuOT CP>#ǝwVyWbxNy?eUt5h `6g+EyŨ;aCl  A|>ߦƞZF[T+ 38<>!XZ&{g)pfKڃ r\WW#Npv\@v5YEO_AqyۺSQoQ@L_Oҹ7C}I1q]a+Uϥ;s JX7 E߿.G=o33g,LGr?L YeU@A9)Jd\5zЏL ''KĤ@@()P>ȁIwH8=)e>V{V 6'wV(r|jLm(o;E9PS>clu٤=B|lP9ݯ9Q 3x+>/+ߙ1,H!s5lAJ^_MNUfB}Lf\"`GFO[(Eqlw1 Npuq 6ZCzDk=ߍK3Ś?]E&OU/Y[52+q+8,>|}>վi72guU(H@N :}p?dIq &Aw lYF iA 椚?O++% u0'`{/9sL[ll65tS:S)NP{\OP<73t> O~4U ~~ ?'Qت8^Yr>zA }ja0 ] j<@]y`{^wM}G8i[ o{U8wnxJSYZdْd=Ȳip   `0 A Dv!kF5sZ wQT }*)oYPpy@q.k3 8N _@s%N Hc0 Q΀Y}ރ>gvFg9.E}P b?^#uFI-Oݽu'څߞ8%Y/B)V\ =Od9Nq'0, 0zxw+`0g^q-+{Vvj }Fozr6[Ӑ8 r'Na `0w`0Rcke0 `0 `0 `0 `0 `0 `0 `0 `0 `0 `0 `0 `0 `0 `0'_␈`0 `0V [EuEĿ O SS s0Ӝ`f5#pKi `0 B, N@)(0l_6X~AQEAPuU@|"tg09!oba? jX`0  Y|(5wbMb OMRn`0V 7K'k" `0g %V?&`C cu1_&vǼL#G4zbr/b9b:4N\ vS]lMw~6AWf;߻7]YӈrgD~߈<:#q>QdJj!S[ .(mhm4Ku8k/ \aİPmҞHl+^.3;aazTHTǿFnN[9؅r8qy%y 5v;|if N&@)lWh 6-F8&J nzu3v H,L<Pߋ;#M is^ ȱAHC+ 5HﯼlA]?G[~0ݣ/k^;E]@(EmT+v&hakzNӿ׸_5|@57Vt;p.FMMp/U3̞p«G em&:e3a!Y;2+6 {H?gH_4 Mn4=?mAR[V #>L ن{Qv0ru?^rbuLv5DD}%|uJ䯼y"L'rMV؋Mk 2p>lǹph;8H!tDKj>K⺳8lj~;KFGE@f!~uCPW5śF/8W(nNls~ɉ[ȳ9c CȦ?}o>+? GF5/D?|VgxY - #6X{?űv_GaX [?ʾ=eݰ=q^n(-% ; k6eS>Zyω"lÿ'SlZzB<=o4fVM."!(lBw OA{JvU<{_r棶  ] ޻t{q > ;䁯^WO[+zӻ='s_3\@z )R;Nua|~Eu;7ت bh۔T9ʇm.(!5uh'?|>HERl]??ʤosn@ƱK]hͅםHX<ؔ=KH'yp #q11|mg|T>~Mⶩ)>AO w1H?:ze81tBYi#.V-ҋ|ߡ%#adKj,ŵg.5KnGǒfgV;Ld?k."Uʫ (U^]D7h}e3ߪkfgX1}88ek#aC;!է^8a^껌ddX{/!Վ=5sS]h$fAlGNIo m-al+~wϿE6Nu߅`,'MU!u_'t_aqLcF}4NM$-Rn)ʹzl$:u]ikwj{ƃ"{Y׿֞F'Zc4V8Vx=@mRҗ+R˫BG6{ddV$I=I",5YAL ɇh/L_I1 ѯ <$Ӟflj]OL/1gO5ْt>3u ]Uh jhN@Auh|'\*c(J[rՔtVdL>ڼ~,Vo64g6~xܧggj+ؚٗZ>%ZlZ?2UXJY/1WF?*sU~[kbg&DTzngi |yJb&p hjME{)CT= \s';GnQ/h= )Я kom^R|摟cҁl7^ɇ]I <;zKzR"MMoKzTdИ 9G[EկV̈N4A$QD6 ]\W||-c> 2,M%miXm7]6MKҋla:g є-iUP==_AZ&*޲ L_ؠWq.D񣹯i?V^Q(cބ=H*>ğ Ȗ?ڒ-Uj$1CdS@:юҀEC/Ih# }L ~_T1j䆂rH_!&oCkc{$:٥ehZ\hV&71Hm%q[>j&e&+0r-ȯ7Sbƀbز$QHQӱةԚ͘s3hM>6 l8|h|=Bsod4\J'>!rW@iL|_6cH4$Cs1x42S2X[?dwa'Bq3 s(S^p&~F~˖fmLKTe|%$ođ7R#U(0\b֪1QN)Jlt H;$;(^#ZhhyGcFxӱ8Wt(g%ľ2{{J܇_^ 2uŎzosK{}l*lnL8^ndӮYCF.ط'X8A:?|5?{x'?[\b^zIӺ8o 2n/(裕f C2C޷o$w(g{mVL3ד<ҿAz,{EΣOFQ>(#f?rDԹ 5hcZOD}N!G!O&ўtcF>P>VK+}pN|F)N)~h =@=a|՗jPd,Y!cddgfIYΰ!=kvJ! _NHOp'_5l))K6![{B3`ЩXW~B^tؒhX'"ֽLxBzC6*ϓM&;=siZSLڴvJ|\o8֮ӎ1;r_n@,yq">s0O#1hˍ' e_AsGk'9ݤ8uI<.@S Z^8(kOuL3Hk6PW)>1=/yFX[hlErͼ_s{{wI^GF9JdO)ʙ폥=5E&Mlu |Q}UZۨ6.l@t?u +cF|qH ]Bn#fvߍ~97{+jqk7׺O}{eJ'!ɧ7m;6TI# #VޑM\6Un]+'g ·?WzU6ϱ+q>>a7:7dtػzT!D;d޻!3xk}Y"u-}{D]]orBS@5032TGBS ]j QByo\ю';꣕1[11m}67މ1{3Od Ȟ0-'ZY) /Ԫ64w-^|ڮQ\Y#^^/Mj^3.Wӯ lՖO(NB|.{7<(Ue߬<,VbqܝL'6\F;d'rv&u4>a:k]+SO_V ›4ӧ5޿8Aws 4X{!>E wI{Lhrށgښrvt#Yҽ;0)ѾH/FA ط!/D#bQ|)jChD|WyJ v}kTЄ+ZB(H?vګ 4VcCf|xv;Zr_ީ+p`~SVԵЕkVXoK|3p{5|ϱ=ڞ>+#ZB` -GČ {;z&^u]Qkž ]}R^KϕᘕX3p XQ/FwnPvv#Hƺ"o0܊r]{uQE]AQz:sw8jhCgc %B'g+Fvv䚜c3cyf%K %p'aԯл]w3x\>[Bݴ-!K3 d1F^82dcKGur牘6s鬚|8<ݧr,k:d[l魵)..V胂}ZKu|q@o+ ?4JʩվV6~!k~oW'ᳰOڋ_*֧irMX ͇C+krBSPH%QMLfI]Dv d;kgua Mizˏ\h>[,8UIىX aeF&O$xǴN#y~1Y 71WsC,[W:sno7ehBDtz%rbsO>_ҾL3_kw5W tiv~AhD o#tpum.GRMz:ԘM%mzt6upHn!͗t(J|ߧ?)gu= mNEĂRFgY9C2]Qu&#kDw!5l_;CVIɕ/ /꣕1rldZ=/^;VF{^uAÚJ!m(K3%IWᕃ>i[ZΡ:JF4Pz7iͱbK'SO#krlxH q!]nqaQY?;`?2)vNϨQߊݛΰc}/L)Eԓ^Qg}jSfX33[[Md:M;OHٕkO϶4_/e,d)h-4kޓ.'VדBDlJ|rΜy\a%l~rΧ|]}]k^]od.J} o9N`wƖp4v\83xGiK~NØj.Ck͕hm 1V,A6׺@fgu&Y=4s>[ }Z'{%yOOi=)9ԄcT>8<!)b-.Z:qrr * oNYg7;l ɵyأcv6}̦O>ZlAq6my.VXd.J} o9N`S\5-5&G`v4) 64)r/Qc)N"2q{m]i7KI_!j7V=v^no J1_ &D.KI|`T8][ܧzk!|zR&-pTL />rWNz@k/\8 yeέ*'g>ew8SikiU+I7"dL'E)ࢳ4e[xg˴ma\ocKJNRJ| o9N燏`/iJ 1}lϾ:eMCs ;#f5k2Ax,Rk{=-M5^w;Y+g-E Yۊhbٮ-V缄šs*Ϝ2~\c?G*֓2lt]kkž3h뇭UIzֻ}m#aYk #cU\`qZS6뤔8Vǧ>w`ROyvs˵%s%>Wy~[ȧT``<{ӭﭶN2a~2>[xzDۙ֓ `䒜x-'!SMX=,}{ʽ\im `0 `0 `0 `0 `0 `0 `0 `0 `0 `0 `0 `0ѿ?8z$$If!vh#v$:V l t065$p ADyK yK http://www.cdc.gov/immigrantrefugeehealth/guidelines/domestic/immunizations-guidelines.htmlyX;H,]ą'cDyK yK zhttp://www.cdc.gov/vaccines/schedules/index.htmlyX;H,]ą'cDyK yK http://www.cdc.gov/vaccines/hcp/acip-recs/index.htmlyX;H,]ą'cSDyK yK http://www.mass.gov/eohhs/gov/departments/dph/programs/id/immunization/guidelines-and-schedules.htmlyX;H,]ą'cDyK yK http://www.uscis.gov/portal/site/uscis/menuitem.5af9bb95919f35e66f614176543f6d1a/?vgnextoid=eb1f3591ec04d010VgnVCM10000048f3d6a1RCRD&vgnextchannel=db029c7755cb9010VgnVCM10000045f3d6a1RCRDyX;H,]ą'cSDyK yK http://www.mass.gov/eohhs/gov/departments/dph/programs/id/immunization/guidelines-and-schedules.htmlyX;H,]ą'cDyK yK Rhttp://www.cdc.gov/vaccines/yX;H,]ą'cDyK yK lhttp://www.cdc.gov/mmwr/pdf/rr/rr6002.pdfyX;H,]ą'cDyK yK jhttp://www.immunize.org/catg.d/p5122.pdfyX;H,]ą'cCDyK yK http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/foreign-products-tables.pdfyX;H,]ą'cDyK yK zhttp://www.cdc.gov/vaccines/schedules/index.htmlyX;H,]ą'c9DyK yK http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/a/age-interval-table.pdfyX;H,]ą'cDyK yK http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/polio.htmlyX;H,]ą'cSDyK yK http://www.mass.gov/eohhs/gov/departments/dph/programs/id/immunization/guidelines-and-schedules.htmlyX;H,]ą'cIDyK yK http://www.mass.gov/eohhs/gov/departments/dph/programs/id/immunization/school-requirements.htmlyX;H,]ą'cDyK yK http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.htmlyX;H,]ą'cDyK yK zhttp://www.cdc.gov/vaccines/schedules/index.htmlyX;H,]ą'cDyK yK http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.htmlyX;H,]ą'c$$If4 !vh#v#v#v :V l0 555 /  / /  4a4 yti9$$If4 !vh#v#v#v :V l0 555 /  / /  4a4 yti9$$If4 !vh#v#v#v :V l0 555 /  / /  4a4 yti9$$If4 !vh#v#v#v :V l0 555 /  / /  4a4 yti9$$If4 !vh#v#v#v :V l0 555 /  / /  4a4 yti9DyK yK zhttp://www.cdc.gov/vaccines/schedules/index.htmlyX;H,]ą'cDyK yK http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.htmlyX;H,]ą'cDyK yK xhttp://www.cdc.gov/vaccines/schedules/index.htmyX;H,]ą'cDyK yK http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.htmlyX;H,]ą'cDyK yK xhttp://www.cdc.gov/vaccines/pubs/preg-guide.htmyX;H,]ą'ceDyK  yK http://www.cdc.gov/immigrantrefugeehealth/exams/ti/civil/vaccination-civil-technical-instructions.htmlyX;H,]ą'ctbl1DyK yK http://www.mass.gov/eohhs/gov/departments/dph/programs/id/immunization/yX;H,]ą'cDyK yK rhttp://www.cdc.gov/vaccines/recs/default.htmyX;H,]ą'cDyK yK rhttp://www.cdc.gov/vaccines/recs/default.htmyX;H,]ą'cDyK yK Nhttp://vaers.hhs.gov/indexyX;H,]ą'cDyK yK 2http://www.immunize.org/ADyK yK http://www.cdc.gov/immigrantrefugeehealth/guidelines/domestic/immunizations-guidelines.htmlyX;H,]ą'c^+ 2 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH <`< NormalCJ_HmH sH tH `@` Heading 1 $<%59CJKHOJQJkHmHnHuZ@Z Heading 2 $< 569OJQJkHmHnHuT@T Heading 3 $<9OJQJkHmHnHuJ@2J Heading 4$h^ha$>*mHnHuJ@2J Heading 5$^a$5mHnHuJ@2J Heading 6$^a$>*mHnHuJ@2J Heading 7$^a$6mHnHuJ@2J Heading 8$^a$6mHnHuJ @2J Heading 9 $^a$6mHnHuDA`D Default Paragraph FontVi@V  Table Normal :V 44 la (k (No List >*`> Endnote ReferenceH*F @FFooter$ !a$ mHnHuF@FHeader$ !a$ mHnHuD&`!D Footnote ReferenceCJEHH@2H Footnote Text$a$ mHnHu.)@A. Page NumberP@R Body Text 2= ,p@ P !$@ /^@ 5CJOJQJkHXB@bX Body Text$a$$59B* CJ@OJQJkHmHnHujQ@rj Body Text 3$ v/a$!56EHOJQJkHmHnHuXS@X Body Text Indent 3 h^hCJOJQJkHfR@fBody Text Indent 2$ Zh^ha$CJmHnHuj"@jCaption$ v/]a$"5CJ EHOJQJkHmHnHuC@ Body Text IndentD & F ) Zp@ P !$/1$^CJEHOJQJ6U`6 Hyperlink >*B*ph8+@8 X Endnote TextCJFV`F e/FollowedHyperlink >*B* ph2o2  A3B*CJ^JaJphbob  Default 7$8$H$-B*CJOJQJ^J_HaJmH phsH tH H@H "H Balloon Text!CJOJQJ^JaJB'`!B ''Comment ReferenceCJaJ8@28 '' Comment Text#CJ@j@12@ ''Comment Subject$5\jSj _ Table Grid7:V%0%$L$ +Date&LOrL L4~qg-level-2-bullet 'd?aJT@T 7List Paragraph (^CJOJQJ^JaJB^@B ,7 Normal (Web) )d?aJ2o2 R?0A4B*CJ^JaJphPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭V$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3N)cbJ uV4(Tn 7_?m-ٛ{UBwznʜ"Z xJZp; {/<P;,)''KQk5qpN8KGbe Sd̛\17 pa>SR! 3K4'+rzQ TTIIvt]Kc⫲K#v5+|D~O@%\w_nN[L9KqgVhn R!y+Un;*&/HrT >>\ t=.Tġ S; Z~!P9giCڧ!# B,;X=ۻ,I2UWV9$lk=Aj;{AP79|s*Y;̠[MCۿhf]o{oY=1kyVV5E8Vk+֜\80X4D)!!?*|fv u"xA@T_q64)kڬuV7 t '%;i9s9x,ڎ-45xd8?ǘd/Y|t &LILJ`& -Gt/PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!0C)theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] VXZ{:Ax8X[0f }\ %QPh:0%$'+,[1e56Q9<ACE[MQTUY\y^`acegiCpv,xyz~ .ޔQzaäsTXYZ[]^_acdfhijlnprsuwxy{|~Q1$"'-1p5Q9D?C-NS_ocijAjljjlhqv{ӓ UVW\`begkmoqtvz}a&Y) K  D ^ c a!!!!O"S"## $S$$$0'1N1;=<y<<<=Q*RYRY Z`ZqZZZqq:rJrrr:{y{{{-|\|ԋ<V'aٗY\Ę XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX}!!@ @H 0(  0(  B S  ?- _Hlt369962307 _Hlt369962308 _Hlt371324998 _Hlt371324999 _Hlt365635848 _Hlt365635849 _Hlt368937412 _Hlt371324992 _Hlt371324993 _Hlt365635898 _Hlt365635899 _Hlt365635917 _Hlt365635918 _Hlt369706242 _Hlt369706243 _Hlt371325896 _Hlt371325897 _Hlt363046649 _Hlt369886616 _Hlt369886617 _Hlt365636850 _Hlt365636851 _Hlt369961993 _Hlt369961994 _Hlt363046817 _Hlt363046818 _Hlt369960576 _Hlt369960577 _Hlt369960583 _Hlt369960584 _Hlt365642507 _Hlt365642508 _Hlt369960598 _Hlt369960599 _Hlt363047950 _Hlt363047951 _Hlt365642582 _Hlt365642583 _Hlt369960608 _Hlt369960609 _Hlt365642599 _Hlt365642600 _Hlt369960629 _Hlt369960630 _Hlt3630479920 0 > > C C C F F *13131?1?1C<C<X<X<%%@@@@@@@@@ @ @ @ @ @@@@@@@@@@@@@@@@@@@ @!@"@#@$@%@&@'@(@)@*@+@,@1 1 ? ? D D D ^ ^ +14141@1@1D<D<Y<Y<&&3STUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~tzz,,""[)[)x*x*X///%0%0&c&cyyOOCKK::FF      !"#$%&'()*+,-./012{99""h)h)|*|*e///20203c3cSSHYYțțGGSS  !"#$%&'()*+,-./0129/*urn:schemas-microsoft-com:office:smarttagsState92*urn:schemas-microsoft-com:office:smarttagsplaceB3*urn:schemas-microsoft-com:office:smarttagscountry-region8 *urn:schemas-microsoft-com:office:smarttagsCity  3232/2322/32323232322333232323232323232 2/32//232/2J E# $G$$%%0O1o<=QZR[RlR{RRSSYaZ&[*[@aDaq9r{{\˜Ę  UZ]7%<%:^:EIOIo[r[5_:_K}N}9Ah 33333333333333c } ##$S$$$%&&Y(a(0O1<=EI]IQZR&U>UYaZaubbbd$de4effhhkkSmfmnnnn[ppq;rrswwxy:{{3h\Ę j< tc #$S$$0O1<=QZRYaZq;r:{{\Ę  l} 4<r.T74HK]hs ht =#4zp(F֖:H+zq S-lnf-^q*/F&6ꭎu=ۄ+VtK& "wA`Ӣf3k"qnar| *   ^ `OJQJo( ^`OJ QJ o(o ^`OJQJo( ^`OJQJo( PP^P`OJ QJ o(o   ^ `OJQJo( ^`OJQJo( !!^!`OJ QJ o(o $$^$`OJQJo(h^`OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHhPP^P`OJ QJ ^J o(hHoh  ^ `OJQJo(hHh^`OJQJo(hHh!!^!`OJ QJ ^J o(hHoh$$^$`OJQJo(hH ^`OJQJo( HH^H`OJ QJ o(o ^`OJQJo( ^`OJQJo( ^`OJ QJ o(o ^`OJQJo( X X ^X `OJQJo( (#(#^(#`OJ QJ o(o %%^%`OJQJo(@h ^ `.h^`OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHhPP^P`OJ QJ ^J o(hHoh  ^ `OJQJo(hHh^`OJQJo(hHh!!^!`OJ QJ ^J o(hHoh$$^$`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh  ^ `OJQJo(hHhUU^U`OJ QJ ^J o(hHoh%%^%`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh"^`B*CJOJQJo(phhHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hHh^`B*^Jo(ph.h^`B*CJOJQJo(phhpLp^p`L^J.h@ @ ^@ `^J.h^`^J.hL^`L^J.h^`^J.h^`^J.hPLP^P`L^J.h^`OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHhPP^P`OJ QJ ^J o(hHoh  ^ `OJQJo(hHh^`OJQJo(hHh!!^!`OJ QJ ^J o(hHoh$$^$`OJQJo(hH^`B*OJQJo(phhH88^8`OJ QJ ^J o(hHo^`OJQJo(hH  ^ `OJQJo(hH  ^ `OJ QJ ^J o(hHoxx^x`OJQJo(hHHH^H`OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hHhh^h`B*CJ^Jo(ph. 88^8`OJ QJ o(o ^`OJQJo(   ^ `OJQJo(   ^ `OJ QJ o(o xx^x`OJQJo( HH^H`OJQJo( ^`OJ QJ o(o ^`OJQJo(^`5^J.^`CJOJPJQJo(pp^p`^J.@ @ ^@ `^J.^`^J.^`^J.^`^J.^`^J.PP^P`^J.^`CJOJQJo(^`B*CJ^Jo(ph. PP^P`OJQJo(   ^ `OJQJo(   ^ `OJ QJ o(o ^`OJQJo( ^`OJQJo( ``^``OJ QJ o(o 00^0`OJQJo(h^`B*CJOJQJo(phh^`B*CJOJQJo(phhpLp^p`L^J.h@ @ ^@ `^J.h^`^J.hL^`L^J.h^`^J.h^`^J.hPLP^P`L^J.^`B*OJQJo(phhH88^8`OJ QJ ^J o(hHo^`OJQJo(hH  ^ `OJQJo(hH  ^ `OJ QJ ^J o(hHoxx^x`OJQJo(hHHH^H`OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`B*CJOJQJo(ph^`B*CJ^Jo(ph. PP^P`OJQJo(   ^ `OJQJo(   ^ `OJ QJ o(o ^`OJQJo( ^`OJQJo( ``^``OJ QJ o(o 00^0`OJQJo(h"^`B*CJOJQJo(phhHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh  ^ `OJQJo(hHhXX^X`OJ QJ ^J o(hHoh((^(`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hH@h ^`OJQJo( ^`OJ QJ ^J o(hHo pp^p`OJQJo(hH @ @ ^@ `OJQJo(hH ^`OJ QJ ^J o(hHo ^`OJQJo(hH ^`OJQJo(hH ^`OJ QJ ^J o(hHo PP^P`OJQJo(hH ^`OJQJo(^`OJQJo(hH ^`OJQJo( ^`OJQJo( PP^P`OJ QJ o(o   ^ `OJQJo( ^`OJQJo( !!^!`OJ QJ o(o $$^$`OJQJo(K]7l} | =#s S-<f-wA`6 q*/3kH+VtKqu=p(arF @h  ^ `OJQJo(E @h ^`OJQJo(ڎ4                 ڎ4                          ,>         3!                B                 Y1        Y13!       B        Y1        ,>                J0V        #!FJ._2 2 ^\zDLe vh/q?*._/I,.ZdS4:-\_hvh/ 5`f#0\z# 1#l2^Na># 1+pHS4:-!FJhvCqL_wDLCqLq_l2.Zde  5`f\_h/I,\vn+pHhvq__wq?*Ix6,a<i9HpP^M T r X $d2qjY /Nq$_[s.q c) [$][ Oq!#% R%x%''X'<)*+/+F+B-,o-I.K.0_05233a3U 4.4267F6[67,7eb798PF8i8q'93:YD:|I;<>Vb>iz>K?R?Q@! CpD =F'GjG"H VIpJ>zK6NbOOP-XQ*TSQTtU@T.iuw& :#uP rM@t=ae/@@Unknown  G*Ax Times New Roman5Symbol3. *Cx Arial7GeorgiasAdobe Garamond ProAdobe Garamond Prok Myriad Pro LightMyriad Pro Light5. .[`)Tahoma7.@Calibri;Wingdings?= *Cx Courier NewA$BCambria Math"hscgscgʂNʂN!4mm 2qHP ?262! xx G900979 \               Oh+'0<   $,4G900979Normal 2Microsoft Office Word@@{@na̻@na̻ʂ՜.+,D՜.+,< hp  STATE LABORATORYNm G Title 8@ _PID_HLINKSAh%hW\http://www.cdc.gov/immigrantrefugeehealth/guidelines/domestic/immunizations-guidelines.htmlLHThttp://www.immunize.org/94Qhttp://vaers.hhs.gov/indexIN-http://www.cdc.gov/vaccines/recs/default.htmIK-http://www.cdc.gov/vaccines/recs/default.htmftHHhttp://www.mass.gov/eohhs/gov/departments/dph/programs/id/immunization/s=Eghttp://www.cdc.gov/immigrantrefugeehealth/exams/ti/civil/vaccination-civil-technical-instructions.htmltbl1nyB0http://www.cdc.gov/vaccines/pubs/preg-guide.htmw8?Dhttp://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html8d<0http://www.cdc.gov/vaccines/schedules/index.htmb'9Dhttp://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.htmlU61http://www.cdc.gov/vaccines/schedules/index.htmlb'3Dhttp://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.htmlU01http://www.cdc.gov/vaccines/schedules/index.htmlw8-Dhttp://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.htmlm:*`http://www.mass.gov/eohhs/gov/departments/dph/programs/id/immunization/school-requirements.htmlI]'ehttp://www.mass.gov/eohhs/gov/departments/dph/programs/id/immunization/guidelines-and-schedules.html6f$Chttp://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/polio.html8s!Xhttp://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/a/age-interval-table.pdfU1http://www.cdc.gov/vaccines/schedules/index.htmlX]http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/foreign-products-tables.pdfO)http://www.immunize.org/catg.d/p5122.pdf*http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdfE http://www.cdc.gov/vaccines/I]ehttp://www.mass.gov/eohhs/gov/departments/dph/programs/id/immunization/guidelines-and-schedules.htmlos http://www.uscis.gov/portal/site/uscis/menuitem.5af9bb95919f35e66f614176543f6d1a/?vgnextoid=eb1f3591ec04d010VgnVCM10000048f3d6a1RCRD&vgnextchannel=db029c7755cb9010VgnVCM10000045f3d6a1RCRDI] ehttp://www.mass.gov/eohhs/gov/departments/dph/programs/id/immunization/guidelines-and-schedules.htmlP5http://www.cdc.gov/vaccines/hcp/acip-recs/index.htmlU1http://www.cdc.gov/vaccines/schedules/index.html%h\http://www.cdc.gov/immigrantrefugeehealth/guidelines/domestic/immunizations-guidelines.html  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#%&'()*+-./01234567<Root Entry FHs̻>Data _1Table~WordDocument=fSummaryInformation($DocumentSummaryInformation8,CompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q